Bioray Biotech Co., Ltd (TPEX:7561)
Taiwan · Delayed Price · Currency is TWD 22.45
-2.15 (-8.74%)
Sep 8, 2026, 12:55 PM CST
Bioray Biotech Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 605 | 618 | 635 | 930 | 901 | 1,290 | |
Market Cap Growth | -31.61% | -2.69% | -31.64% | 3.17% | -30.18% | 56.23% |
Enterprise Value | 567 | 515 | 586 | 911 | 896 | 1,226 |
Last Close Price | 20.45 | 19.82 | 20.19 | 29.30 | 28.22 | 44.10 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 31.54 | 19.17 | 634.18 | - | 1802.11 | - |
PS Ratio | 2.92 | 2.78 | 3.15 | 4.85 | 4.73 | 8.72 |
PB Ratio | 1.40 | 1.37 | 1.51 | 2.14 | 2.00 | 3.55 |
P/TBV Ratio | 1.40 | 1.37 | 1.51 | 2.15 | 2.01 | 3.58 |
P/FCF Ratio | 9.51 | 8.68 | 47.32 | - | - | - |
P/OCF Ratio | 9.48 | 8.63 | 38.16 | - | 363.62 | 146.17 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.74 | 2.31 | 2.90 | 4.75 | 4.70 | 8.29 |
EV/EBITDA Ratio | 13.33 | 9.90 | 48.59 | - | 56.76 | 230.50 |
EV/EBIT Ratio | 28.08 | 13.58 | - | - | - | - |
EV/FCF Ratio | 8.91 | 7.22 | 43.61 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.17 | 0.10 | 0.20 | 0.16 | 0.22 | 0.15 |
Debt / EBITDA Ratio | 1.67 | 0.76 | 4.26 | 13.55 | 4.68 | 4.99 |
Debt / FCF Ratio | 1.12 | 0.65 | 6.39 | - | - | - |
Net Debt / Equity Ratio | -0.09 | -0.35 | -0.22 | -0.06 | -0.08 | -0.20 |
Net Debt / EBITDA Ratio | -1.12 | -3.05 | -7.67 | 16.42 | -2.42 | -13.70 |
Net Debt / FCF Ratio | -0.60 | -2.23 | -6.88 | 2.53 | 0.67 | 11.85 |
Asset Turnover | 0.38 | 0.41 | 0.37 | 0.34 | 0.36 | 0.31 |
Inventory Turnover | 2.04 | 2.16 | 2.40 | 2.10 | 2.24 | 1.72 |
Quick Ratio | 2.15 | 6.05 | 5.33 | 3.52 | 2.77 | 2.20 |
Current Ratio | 4.73 | 7.85 | 6.98 | 5.00 | 3.69 | 2.83 |
Return on Equity (ROE) | 4.40% | 7.38% | 0.23% | -2.61% | 0.12% | -2.16% |
Return on Assets (ROA) | 2.32% | 4.38% | -0.50% | -2.12% | -0.04% | -1.08% |
Return on Invested Capital (ROIC) | 4.02% | 9.52% | -0.85% | -4.71% | -0.07% | -2.80% |
Return on Capital Employed (ROCE) | 4.10% | 7.60% | -0.90% | -3.90% | -0.10% | -2.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.17% | 5.22% | 0.16% | -1.24% | 0.06% | -0.56% |
FCF Yield | 10.52% | 11.53% | 2.11% | -1.16% | -6.34% | -0.48% |
Dividend Yield | 5.81% | 4.79% | - | - | 0.71% | - |
Buyback Yield / Dilution | -0.05% | 0.76% | 0.83% | -7.37% | -4.67% | -0.14% |
Total Shareholder Return | 5.76% | 5.56% | 0.83% | -7.37% | -3.96% | -0.14% |